Treasury Board of Canada Secretariat
www.tbs-sct.gc.ca
Common menu bar links
Breadcrumb Trail
ARCHIVED - Patented Medicine Prices Review Board - Report
This page has been archived.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Section III: Supplementary Information
Financial Highlights
Future-Oriented Financial Statements
The future-oriented financial highlights presented within this RPP are intended to serve as a general overview of the PMPRB’s financial position and operations. These future-oriented financial highlights are prepared on an accrual basis to strengthen accountability and improve transparency and financial management.
Future-oriented financial statements can be found on the PMPRB’s Web site at http://www.pmprb-cepmb.gc.ca/CMFiles/reports%20to%20parliament/Future%20Oriented%20Financial%20Statements%20Final%20Signed.pdf.
| $ Change | Future-Oriented 2012–13 |
Future-Oriented 2011-12 |
|
|---|---|---|---|
| Total Expenses | 28% | 13,138,511 | 10,291,772 |
| Total Revenues | -100% | (0) | (11,195,426) |
| Net Cost of Operations | -1554% | $13,138,511 | ($903,654) |
Total Expenses
The PMPRB is projecting $13.1 million in expenses based on 2012-13 Main Estimates and accrued information. This amount does not include supplementary estimates. It represents an increase of $2.8 million from 2011-12 projections.
The expenses by Strategic Outcome are as follows: Patented Medicine Prices Regulation Program $8.2 million; Pharmaceutical Trends Program $1.5 million; and Internal Services $3.4 million, including vacation pay and compensatory leave and Employee future benefits.
The expenses are broken down as follows: Salaries and wages, $7.6 million; Professional and special services, $4.1 million; Accommodation, $734.0 thousand; Utilities, materials and supplies $345.0 thousand; and Other $322.4 thousand.
Total Revenues
The money reported as non-respendable revenue does not represent revenues generated by the PMPRB. This money is a result of payments made by patentees to the Government of Canada through Voluntary Compliance Undertakings (VCUs) or Board Orders to offset excess revenues. The Minister may enter into agreements with any province or territory respecting the distribution to that province/territory of amounts received by the Receiver General, less any costs incurred in relation to the collection and distribution of those amounts.
| $ Change | Future-Oriented 2012-13 |
Future-Oriented 2011-12 |
|
|---|---|---|---|
| Total assets | 3% | $824,383 | $799,101 |
| Total liabilities | 6% | 2,086,109 | 1,963,219 |
| Total Equity | 8% | (1,261,728) | (1,164,118) |
| Total Liabilities and Equity of Canada | 3% | $824,381 | $799,101 |
Assets by Type
Total assets are anticipated to be $824.4 thousand for 2012-13, an increase of $25.3 thousand from 2011-12 projections.
Due from Consolidated Revenue Fund is projected to be $582.7 thousand for 2012-13, representing a decrease of $20.0 thousand from 2011-12 estimates. Accounts receivable and advances are expected to be $241.7 thousand. Trend analysis indicates that the net change in the PMPRB’s Accounts receivable and advances will be a net increase of $45.3 thousand.
Liabilities by Type
Total liabilities are anticipated to be $2,086.1 thousand for 2012-13, a net increase of $122.9 thousand from 2011-12 projections.
The breakdown of liabilities is as follows: Accounts payable and accrued liabilities $803.3 thousand; Vacation pay and compensatory leave $365.4 thousand; and Employee future benefits $917.4 thousand.
List of Supplementary Information Tables
All electronic supplementary information tables found in the 2012–13 Reports on Plans and Priorities can be found on the Treasury Board of Canada Secretariat website.
- Greening Government Operations;
- Sources of Respendable and Non-Respendable Revenue;
- Upcoming Internal Audits and Evaluations over the next three fiscal years;
Section IV: Other Items of Interest
Organizational Contact Information
The Patented Medicine Prices Review Board
Box L40
Standard Life Centre
333 Laurier Avenue West
Suite 1400
Ottawa, Ontario K1P 1C1
Telephone: (613) 952-7360
Toll-free no.: 1-877-861-2350
Facsimilie: (613) 952-7626
TTY: (613) 957-4373
Email: pmprb@pmprb-cepmb.gc.ca
Website: www.pmprb-cepmb.gc.ca
Additional Information
PMPRB Annual Report 2010 - http://www.pmprb-cepmb.gc.ca/english/view.asp?x=91
Quarterly NEWSletter - NEWSletter
Patentee’s Guide to Reporting - http://www.pmprb-cepmb.gc.ca/english/view.asp?x=146
Compendium of Policies, Guidelines and Procedures, June 2009 (Updated June 30, 2011) http://www.pmprb-cepmb.gc.ca/english/View.asp?x=1206&mp=808
Patent Act (http://laws.justice.gc.ca/en/P-4/index.html)
Patented Medicines Regulations (http://laws.justice.gc.ca/en/P-4/SOR-94-688/index.html)
Notes:
-
1 Type is defined as follows: previously committed to—committed to in the first or second fiscal year prior to the subject year of the report; ongoing—committed to at least three fiscal years prior to the subject year of the report; and new—newly committed to in the reporting year of the RPP or DPR.
-
2 The PMPRB has only one Strategic Outcome (SO), and all priorities are linked to that SO. Links to Program Activity (PA) are indicated in this column, for each priority.
